A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease  by Fouque, D. et al.
A proposed nomenclature and diagnostic criteria for
protein–energy wasting in acute and chronic kidney
disease
D Fouque1,17, K Kalantar-Zadeh2,17, J Kopple2, N Cano3, P Chauveau4, L Cuppari5, H Franch6,
G Guarnieri7, TA Ikizler8, G Kaysen9,10, B Lindholm11, Z Massy12,13, W Mitch14, E Pineda15, P Stenvinkel11,
A Trevinho-Becerra15 and C Wanner16
1Department of Nephrology, Hopital Edouard Herriot, Universite´ Lyon 1, U870 INSERM, Lyon, France; 2Division of Nephrology and
Hypertension, Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center, University of California (UCLA), Torrance,
California, USA; 3CRNH Auvergne, 58 rue Montalembert, Clermont-Ferrand, France; 4Service de Ne´phrologie, CHU Bordeaux, Place
Ame´lie Raba-Le´on, Bordeaux, France; 5Division of Nephrology, Federal University of Sa˜o Paulo, Sa˜o Paulo, Brazil; 6Renal Division, Emory
University School of Medicine, Atlanta, Georgia, USA; 7Division of Internal Medicine, Department of Clinical, Morphological and
Technological Sciences, University of Trieste, Trieste, Italy; 8Division of Nephrology, Vanderbilt University Medical Center, Nashville,
Tennessee, USA; 9Departments of Medicine and Biochemistry and Molecular Medicine, University of California (UC) Davis, Davis,
California, USA; 10VANCHCS, Mather, California, USA; 11Division of Baxter Novum and Renal Medicine, Department of Clinical Science,
Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; 12INSERM ERI-12, Amiens, France; 13Amiens University Hospital,
UPJV, Amiens, France; 14Nephrology Division, Baylor College of Medicine, Houston, Texas, USA; 15Faculty of Medicine, Autonomous
National University of Mexico, Mexico City, Mexico and 16Department of Medicine, University Hospital, Wuerzburg, Germany
The recent research findings concerning syndromes of
muscle wasting, malnutrition, and inflammation in
individuals with chronic kidney disease (CKD) or acute kidney
injury (AKI) have led to a need for new terminology. To
address this need, the International Society of Renal Nutrition
and Metabolism (ISRNM) convened an expert panel to review
and develop standard terminologies and definitions related
to wasting, cachexia, malnutrition, and inflammation in
CKD and AKI. The ISRNM expert panel recommends the
term ‘protein–energy wasting’ for loss of body protein mass
and fuel reserves. ‘Kidney disease wasting’ refers to the
occurrence of protein–energy wasting in CKD or AKI
regardless of the cause. Cachexia is a severe form of
protein–energy wasting that occurs infrequently in kidney
disease. Protein–energy wasting is diagnosed if three
characteristics are present (low serum levels of albumin,
transthyretin, or cholesterol), reduced body mass (low or
reduced body or fat mass or weight loss with reduced
intake of protein and energy), and reduced muscle mass
(muscle wasting or sarcopenia, reduced mid-arm muscle
circumference). The kidney disease wasting is divided into
two main categories of CKD- and AKI-associated
protein–energy wasting. Measures of chronic inflammation or
other developing tests can be useful clues for the existence
of protein–energy wasting but do not define protein–energy
wasting. Clinical staging and potential treatment strategies
for protein–energy wasting are to be developed in the future.
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There has been an increase of mechanisms causing syndromes of
wasting, malnutrition, inflammation, and their interrelationships
in individuals with chronic kidney disease (CKD) or acute
kidney injury (AKI). Currently, there appears to be some
confusion regarding the terms and definitions used for
conditions associated with loss of muscle and fat tissue,
malnutrition, and inflammation in patients with CKD or AKI.
Use of non-uniform and ill-defined terminologies may lead to
both conceptual errors and misinterpretation of data. The
development of a uniform nomenclature, definition, and
classification for the presence of loss of muscle and fat tissues
(that is, wasting) or the presence of malnutrition and/or
inflammation in individuals with kidney disease could lead to
benefits by engendering a more systematic and rational approach
to both research and the clinical management of such patients.1–3
Other groups have addressed the need for more exact definitions
and stages of illness in kidney disease, including the Kidney
Disease Outcome Quality Initiative (KDOQI)4 and Kidney
Disease Improving Global Outcomes (KDIGO).5–7
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Owing to the foregoing matters, the International Society
of Renal Nutrition and Metabolism (ISRNM) convened an
expert panel to re-examine the terms and criteria used for the
diagnosis of the wasting syndrome, distinct from malnutri-
tion and inflammation in individuals with CKD or AKI.
During the biannual conference of the ISRNM in Merida´,
Mexico, from 28 February to 3 March 2006, and the annual
meeting of the American Society of Nephrology in San Diego,
CA, 16–19 November 2006, the panel met to address these
issues of nomenclature. The current position paper is the
result of these deliberations and expresses the opinion of the
clear majority of the panel.
THE SYNDROMES OF MALNUTRITION, INFLAMMATION,
CACHEXIA, AND WASTING
Surveys using classic measures of nutritional status indicate
that approximately 18–75% of patients with CKD under-
going maintenance dialysis therapy show evidence of
wasting.1,8,9 These syndromes have been referred to as uremic
malnutrition,10,11 uremic (renal) cachexia,12–15 protein–energy
malnutrition,16–18 malnutrition–inflammation atherosclerosis
syndrome,19–21 or malnutrition–inflammation complex (or
cachexia) syndrome.9,22 In the last 5 years, it has become
apparent that many of the measures indicating the presence
of wasting and abnormalities in protein–energy nutritional
status can also be induced by inflammatory processes.23–26
Simply stated, malnutrition refers to abnormalities induced
by an inadequate diet, whereas wasting refers to abnormal-
ities that cannot be corrected solely by increasing the diet.2,3
For example, pure malnutrition can be associated with
reduced serum albumin concentrations, but marked reduc-
tions are unusual, while the presence of inflammation is
frequently associated with a decrease in serum albumin,
where marked reductions are common.27 Inflammation may
also be associated with an increase in protein catabolism that
is presumably related to the elaboration of catabolic or
antianabolic proinflammatory cytokines.28 Thus, malnutrition
refers to the presence of a low-nutrient intake or, at least, an
intake that is inadequate for the nutritional needs of the
individual. In contrast, an increase in proinflammatory cytokines
such as tumor necrosis factor-a and interleukin-6 may cause loss
of protein stores and also can induce anorexia with reduced
nutrient intake.29 The difference is that inflammation or other
problems associated with loss of kidney function (for example,
metabolic acidosis or impaired insulin/insulin-like growth factor-
1 signaling pathways) can impair protein anabolism indepen-
dently of whether adequate nutrition is present.24
The relative contributions of malnutrition or inflamma-
tion to mortality are obscured because many indicators of
malnutrition and inflammation are identical (e.g., low serum
albumin and prealbumin concentrations, protein intake, and
even body weight-for-height measures, such as body mass
index (BMI)).30 Moreover, loss of muscle and fat stores and
inflammation are likely to increase the risk of death from
cardiovascular or cerebrovascular disease (possibly by
promoting vascular endothelial damage26,31–33).
PROTEIN–ENERGY WASTING
Protein–energy wasting (PEW) is the state of decreased body
stores of protein and energy fuels (that is, body protein and
fat masses). This abnormality is often associated with
diminished functional capacity related to metabolic stresses.
Protein or energy depletion can result from an inadequate
diet (for example, anorexia nervosa), but in kidney disease, in
contrast to anorexia nervosa, there are conditions resulting in
loss of lean body mass not related to reduced nutrient intake.
These include nonspecific inflammatory processes; transient,
intercurrent catabolic illnesses;34 nutrient losses into dialy-
sate;35–37 acidemia;38–40 endocrine disorders such as resistance
to insulin,41 growth hormone,42 and insulin-like growth
factor-1;43 hyperglucagonemia;44 hyperparathyroidism;45 and
loss of blood into the hemodialyzer, into feces or by blood
drawing.46 It is possible, but not proven, that malnutrition
may also predispose to inflammatory states as shown in
animal models.47 Thus, we believe that the most desirable
term for describing the syndrome of depletion of protein
mass and/or energy fuel supplies is ‘protein–energy wasting’.
Since protein wasting and energy wasting may occasionally
occur separately from each other, the term ‘protein wasting’
or ‘energy wasting’ may be used to indicate the isolated
occurrence of only one of these phenomena. Potential causes
and consequences of PEW are depicted in Figure 1.
CACHEXIA
Recently, the word ‘cachexia’ has been suggested as a term to
denote PEW included in the setting of kidney disease.12–15,48
Cachexia refers to a very severe form of PEW, often associated
with profound physiological, metabolic, psychological, and
immunological disorders.49 ‘Cachexia is a complex syndrome
that often develops as a serious complication of various
chronic diseases.’50,51 ‘Cachexia carries a very poor prognosis
and almost no therapies for its treatment are approved, apart
from that for acquired immune deficiency syndrome (AIDS)-
induced cachexia.’50,51
The difference in PEW compared to cachexia is that the
latter encompasses only severe forms of metabolic depletion,
whereas PEW can refer to mild degrees of depleted protein
and energy mass. It would seem to be a contradiction to
classify mild protein or energy depletion as cachexia.
Modified terms such as ‘latent cachexia’ neither describe
the body mass or composition of an individual nor
mechanistically denote metabolic processes and are not
recommended,48 whereas cachexia may be used for severe
forms of PEW (Figure 1).
OTHER TERMINOLOGIES
Other terms used to indicate the existence of ‘malnutrition’ in
patients with kidney disease include uremic malnutrition,10,11
protein–energy malnutrition,16–18 malnutrition–inflammation
atherosclerosis syndrome,19–21 and malnutrition–inflammation
complex syndrome.9,22 Because ‘malnutrition’ may indicate
both undernutrition and overnutrition,52,53 there is
an additional interpretational problem when it is used to
392 Kidney International (2008) 73, 391–398
m e e t i n g r e p o r t D Fouque et al.: Protein–energy wasting in kidney disease
describe the wasting syndrome occurring in acute kidney
disease or CKD.53 Clearly characterizing the entire wasting
syndrome as malnutrition will lead to underrecognition of
the role of other contributing factors such as hypercatabo-
lism, inflammation, acidemia, or oxidative stress.3
Some investigators have suggested classifying the wasting
syndrome based on the presence or absence of coexisting
inflammation.20 Oxidative stress may also contribute to
kidney disease-related wasting.54,55 However, we believe that
labeling the problems of patients with kidney disease as
‘inflammatory wasting’ may erroneously imply that the PEW
syndrome is due exclusively to inflammation.
KIDNEY DISEASE WASTING
Individuals with CKD or AKI are at increased risk for PEW,
and the term, kidney disease wasting (KDW), emphasizes this
common association. However, there are many causes of
PEW in individuals with kidney disease, and KDW does not
provide any insights into the different causes of PEW. In
addition, some patients may develop severe PEW before they
develop kidney failure.
For example, a new onset maintenance dialysis patient
who has been severely depressed psychologically all of his
adult life, who has eaten poorly for the last 5 years, and who
has chronic PEW can be diagnosed with KDW even though
the cause of his PEW is not related to kidney disease.
Similarly, a patient with CKD stage 4 and advanced AIDS or
vasculitis can be cachectic, but the PEW is not caused by
kidney disease. The connotation that many people will infer
from the term KDW is that the protein–energy malnutrition
is at least partly caused by kidney disease. The same
disassociation may be found between patients with AKI
and causes of PEW. For example, the causes and medical
management of PEW in a young, previously healthy
individual who develops pancreatitis, sepsis, and AKI may
be quite different from those of an individual 85 years old
with chronic congestive heart failure, chronic obstructive
pulmonary disease, pneumonia, septicemia, and AKI. For
these reasons, the clear majority of the panel members
prefer PEW to KDW for most circumstances. The panel
believes that the term KDW is not a suitable substitute for
PEW but simply implies that PEW is likely to occur in people
with CKD or AKI. Figure 1 contains a schematic representa-
tion of PEW and its complex interrelationships with several
conditions that may lead to or aggravate PEW in kidney
disease.
DIAGNOSIS OF PEW
There are several clinical, nutritional, and biochemical
parameters that may be indicative of PEW in individuals
with kidney disease. The expert panel recommends that four
main and established categories be recognized for the
diagnosis of PEW: biochemical criteria; low body weight,
reduced total body fat, or weight loss; a decrease in muscle
mass; and low protein or energy intakes (Table 1). The panel
recognizes additional measures of nutrition and inflam-
mation, including some currently under development, which
can be regarded as potential clues to the existence of PEW
(Table 2).
Among biochemical indicators that can be used for the
diagnosis of PEW, serum albumin is known to have strong
and consistent outcome-predictability of mortality in epide-
miologic studies of dialysis patients.62–66 Although low serum
albumin is often associated with severe clinical disease states,
the epidemiological relationship to mortality is based upon
the low serum albumin per se and poor outcome. It follows
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Figure 1 | Schematic representation of the causes and manifestations of the protein–energy wasting syndrome in kidney disease.
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from Table 1 that a low serum albumin concentration is not
necessary or sufficient for the diagnosis of PEW, although it is
often present in this condition. Serum prealbumin, also
known as transthyretin,67,68 and cholesterol have also been
studied as nutritional markers in CKD patients.67,69–71 The
expert panel recommends that at least one biochemical
indicator be included when making the clinical diagnosis of
PEW (Table 1). The level of serum C-reactive protein or
other inflammatory markers, including such circulating
proinflammatory cytokines as interleukin-6, may also be
persistently increased in PEW,31,33,72 but these measurements
should not be used as part of the criteria for the diagnosis of
PEW (Table 2).
Among indicators of body mass, BMI is the most
commonly used measure of weight-for-height73–75 and may
be used to assess PEW. However, BMI can be heavily
influenced by fat mass or hydration status. Nonetheless, a low
BMI is a consistent predictor of poor outcome and high
death risk in maintenance dialysis patients.76,77 The ISRNM
panel recommends that a BMI less than 23 kg m2 is a marker
of PEW. The panel also recognizes that the threshold for this
criterion may need further adjustment; especially in some
populations, such as those from southeast Asia, a low BMI
may not indicate pathology.78,79 We also note that these
suggested values of BMI should not be expanded to
recommendations for the general population, because obesity
should be avoided. Notably, the World Health Organization
recommends a BMI range between 18.5 and 25 kg m2 as the
normal range for the general population.80
Unintentional weight loss or reduction in BMI of any
degree should suggest the presence of PEW in individuals
with kidney disease. Currently, the expert panel recommends
that a loss of 5% of non-edematous weight within 3 months
or an unintentional loss of 10% of non-edematous weight
over the past 6 months should be considered an indicator of
PEW, independently of weight-for-height measures.
The panel considered the use of body fat as a percentage of
weight as an additional criterion for wasting, because BMI is
strongly, but not solely, influenced by body fat.81 Moreover, a
decrease in body fat in epidemiologic studies has been
Table 1 | Readily utilizable criteria for the clinical diagnosis of
PEW in AKI or CKD
Criteria
Serum chemistry
Serum albumino3.8 g per 100 ml (Bromcresol Green)a
Serum prealbumin (transthyretin)o30 mg per 100 ml (for maintenance
dialysis patients only; levels may vary according to GFR level for
patients with CKD stages 2–5)a
Serum cholesterolo100 mg per 100 mla
Body mass
BMI o23b
Unintentional weight loss over time: 5% over 3 months or 10% over 6
months
Total body fat percentage o10%
Muscle mass
Muscle wasting: reduced muscle mass 5% over 3 months or 10% over 6
months
Reduced mid-arm muscle circumference areac (reduction 410% in
relation to 50th percentile of reference population)
Creatinine appearanced
Dietary intake
Unintentional low DPI o0.80 g kg1 day1 for at least 2 monthse for
dialysis patients or o0.6 g kg1 day1 for patients with CKD stages 2–5
Unintentional low DEI o25 kcal kg1 day1 for at least 2 monthse
AKI, acute kidney injury; BMI, body mass index; CKD, chronic kidney disease; DEI,
dietary energy intake; DPI, dietary protein intake; GFR, glomerular filtration rate;
nPCR, normalized protein catabolic rate; nPNA, normalized protein nitrogen
appearance; PEW, protein–energy wasting.
At least three out of the four listed categories (and at least one test in each of the
selected category) must be satisfied for the diagnosis of kidney disease-related PEW.
Optimally, each criterion should be documented on at least three occasions,
preferably 2–4 weeks apart.
aNot valid if low concentrations are due to abnormally great urinary or
gastrointestinal protein losses, liver disease, or cholesterol-lowering medicines.
bA lower BMI might be desirable for certain Asian populations; weight must be
edema-free mass, for example, post-dialysis dry weight. See text for the discussion
about the BMI of the healthy population.
cMeasurement must be performed by a trained anthropometrist.
dCreatinine appearance is influenced by both muscle mass and meat intake.
eCan be assessed by dietary diaries and interviews, or for protein intake by
calculation of normalized protein equivalent of total nitrogen appearance (nPNA or
nPCR) as determined by urea kinetic measurements.
Table 2 | Other potential tools (including those still in
development) for assessment of PEW in individuals with CKD
stages 3–5 or AKI
Appetite, food intake, and energy expenditure
Appetite assessment questionnaires
Population-based dietary assessments: food frequency questionnaires
Measuring energy expenditure by indirect or direct calorimetry
Body mass and composition
Weight-based measures: weight-for-height
Total body nitrogen
Total body potassium
Energy-beam-based methods: DEXA, NIR, BIA, and Vector
Bioimpedance Analysis
Underwater weighing and air displacement weighing
14 kDa fragment of actomyosin
Microarrays
Muscle fiber size
Relative proportions of muscle fiber types
Muscle alkaline soluble protein
CT and/or MRI of muscle mass
Laboratory markers
Serum biochemistry: transferrin, urea, triglyceride, bicarbonate
Hormones: leptin, ghrelin, growth hormones
Inflammatory markers: CRP, IL-6, TNF-a, IL-1, SAA
Peripheral blood cell count: lymphocyte count or percentage
Nutritional scoring systems
SGA and its modifications, including DMS56,57 and CANUSA version58
MIS59
Other scoring tools: Wolfson et al.,60 Merkus et al.61
BIA, bioelectrical impedance analysis; CANUSA, Canada–USA study-based modifica-
tion of the SGA; CRP, C-reactive protein; CT, computed tomography; DEXA, dual-
energy X-ray absorptiometry; DMS, dialysis malnutrition score; HD-PNI, hemodialysis
prognostic nutritional index; IGF-1, insulin-like growth factor-1; IL, interleukin (e.g.,
IL-1 and IL-6); MIS, malnutrition–inflammation score; MRI, magnetic resonance
imaging; NIR, near infrared interactance; SAA, serum amyloid A; SGA, subjective
global assessment of nutritional status; SUN, serum urea nitrogen; TNF-a, tumor
necrosis factor-a.
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associated with an increase in the risk of death in
maintenance dialysis patients.82–84 But, the majority of the
expert panel members agree that a total body fat below 10%
in individuals who are not overtly muscular may be
hazardous; there is no consensus on this point and a value
suggesting the presence of PEW would be body fat below
10% of weight.82–84
A reduced muscle mass appears to be the most valid
criterion for the presence of PEW (Table 1).85,86 A popular
term, sarcopenia, has been used to describe the loss of muscle
mass that occurs in elderly patients. Hence, sarcopenia, by
this definition, should not be applied to the PEW of patients
with kidney disease unless this loss of muscle mass occurs in
an elderly individual.
It is often difficult to diagnose low muscle mass or muscle
loss accurately.87 Currently, there are no clinically useful,
uniform and reproducible measures of lost muscle mass and
methods for assessing the presence of accelerated muscle
protein catabolism.88 Some studies have suggested indirect
measures of muscle mass, such as serum creatinine, obtained
immediately before a hemodialysis treatment in maintenance
hemodialysis patients, or the creatinine appearance (net
creatinine generation)89–92 (Table 1). The term ‘creatinine
appearance’ rather than ‘creatinine generation’ is used
because some creatinine is degraded in the intestinal tract93
and the rate of creatinine degradation increases in patients
who have very elevated serum creatinine concentrations.
Thus, without isotopic kinetic studies to quantitate the rate
of creatinine degradation or synthesis, it is not possible to
assess the absolute rate of creatinine generation. We therefore
recommend the term creatinine appearance, which can also
be estimated by measurement of creatinine in 24 h urine
collection and in the collected spent dialysate. The term ‘urea
nitrogen appearance,’ rather than ‘urea generation,’ has been
used for the same reasons.94
The accuracy and reproducibility of serum creatinine as an
indirect measure of muscle mass is not very precise, especially
in dialysis patients receiving different doses of dialysis.77
Nonetheless, in many diseases, there is clinical and pro-
gnostic importance when loss of muscle mass is documented
and hence, the panel agrees that it should be included as a
clinical criterion for the diagnosis of PEW. Emphasis is placed
on assessing the loss of muscle mass because of the
limitations of assessing changes in body weight in patients
with impaired salt and water regulation, and on the fact
that there are many pitfalls in diagnosing the adequacy of
the diet.95,96
Bioelectrical impedance analysis (BIA) has become a
commonly used technique for estimating body water and, by
inference, muscle mass97 (Table 2). The BIA phase angle has
been correlated with mortality rate in maintenance hemo-
dialysis (MHD) patients.98 Vector Bioimpedance Analysis has
been reported as a more sensitive and accurate method for
estimating the state of hydration in chronic dialysis
patients.99 Multifrequency sum of segments bioimpedance
may be more sensitive for estimating muscle mass.100 The
near infrared interactance is a simple method to assess
percent body fat via light emission using near infrared
spectroscopy on the biceps of the dominant arm and has high
correlation with hydrostatic densitometry.101 Near infrared
measurements of body fat have been shown to correlate
significantly with other nutritional measures102,103 and
predict survival84 in maintenance hemodialysis patients.
The panel recognizes that diminished appetite (anorexia)
can be associated with PEW and may herald a poor clinical
outcome.29,104 Hence, an unintentional reduction in dietary
protein intake less than about 0.80 g per kg body weight per
day in maintenance dialysis patients and dietary energy
intake less than about 25 kcal per kg body weight can be
associated with PEW.4 It is also recognized that there are
pitfalls in identifying a decrease in energy intake.95,96 We
recognize that these criteria are quite conservative, and most
maintenance dialysis patients will have dietary protein needs
and most CKD and maintenance dialysis patients will have
energy requirements that are substantially higher than these
values.4 We also note that the amount of dietary protein
needed for patients with stages 3–5 CKD who are not being
treated by maintenance dialysis therapy should be considered
to be an exception to this rule.105,106
In recent years, nutritional scoring systems have been
recommended as practical tools for the diagnosis of
malnutrition in individuals with kidney disease (Table 2).
The KDOQI expert panel for nutrition4 as well as
the European Best Practice Guidelines Wave II have
recommended serial assessments by Subjective Global
Assessment of Nutrition (SGA) in CKD patients who
undergo maintenance dialysis treatment.56,107 There are
additional nutritional scoring systems, some of which are
modified versions of the SGA.56 Currently, there is no
consensus about the relationship of these subjective assess-
ments to the diagnosis of PEW. These scoring systems should
be considered as potential clinical markers of PEW status
(Table 2) but not as definitive diagnostic indicators of
this syndrome.
CONCLUSIONS AND FUTURE STEPS
The purpose of our position paper is to advance a unifying
and practical terminology for the PEW syndrome of loss of
protein mass and energy stores that occurs in many patients
with CKD or AKI. There are a large number of disorders that
can cause PEW in patients with kidney disease, including the
presence of an inadequate diet, the presence of inflammation,
oxidative stress, acidemia, nutrient losses into dialysate,
altered responses to anabolic hormones, increased levels of
unexcreted toxins, and blood loss. It is hoped that a
systematically defined nomenclature and diagnostic criteria
for PEW in CKD and AKI will help to clarify thinking and
communication, enhance the effectiveness of patient care,
and promote more incisive research in this field. Many
questions about the description, classification, and treatment
of KDW need to be addressed: (1) Can nutritional inter-
vention improve the biochemical and clinical disorders related
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to PEW (Table 1)? (2) What is the PEW scoring system that
most effectively predicts morbidity and/or mortality? (3) Is
there a gender impact on appetite, wasting, inflammation, and
outcome? (4) If therapeutic interventions are effective at
improving indicators of PEW, will clinical outcomes, including
survival, also improve? Randomized, well-designed, controlled
trials will be required to answer these and similar questions
concerning PEW in AKI and CKD.
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